Oak Longevity Review: The Pricing Structure Is Genuinely Good — The Eligibility Floor Is Set at a Normal BMI

What Is Oak Longevity?

Oak Longevity trades as Oak Longevity Holdings Corp, contactable at hello@oaklovesyou.com and on 435-244-7757. The affiliate programme lists it as launched on 20 April 2026, making it under four months old at the time of this review, and we could locate no BBB profile, Trustpilot presence or independent review record of any kind.

The core offer is compounded GLP-1 weight management: semaglutide from $119 a month and tirzepatide from $185, sold on terms the site summarises as 'One price · All dosages · No subscriptions'. Alongside that sit oral medications, NAD+ and glutathione, tadalafil, sermorelin and other peptides, and a women's health line covering hormones and sexual health.

The pricing structure deserves genuine credit, because it fixes the two things that most often catch people out elsewhere. Flat pricing across every dose means your cost does not climb as you titrate upward — and since GLP-1 therapy involves stepping the dose up over months, a provider whose price rises with each increase can end up far more expensive than its headline suggests. And no subscription with no membership fee means the medication price is the whole price. Free shipping and free health coaching are included, and Oak says it price-matches any medication.

It also promises same-day approval with no video call required, which is fast even by this market's standards.

Where it comes apart is the marketing layer, and one line in particular about who should be treated.

Pricing & What's Included

The structure here is better than the numbers alone suggest. One price across all dosages removes the single biggest hidden cost in GLP-1 therapy — providers that charge more at each dose step can double your outlay over a year of titration — and no membership fee means there is nothing stacked on top. That is a genuinely well-designed offer. What is less clean is that the site quotes three different prices: $119 for semaglutide and $185 for tirzepatide in the headline, and $167 a month in its own comparison table against competitors. None of the other products — NAD+, glutathione, sermorelin, tadalafil, the women's health line — carries a published price at all. Establish exactly what you will pay, for which medication, before you commit.

Compounded Medication — What Oak Says, and What It Overstates

Oak sells compounded medication, and its disclosure is a mixed picture that is worth reading carefully.

On the credit side, it states the key fact plainly in one of its FAQs: compounded versions 'are not FDA-approved as finished products'. Plenty of competitors never say that at all, and it is the single most important thing a buyer of compounded medication needs to know.

On the other side, the framing around it works hard to minimise it. The FAQ 'Is compounded medication safe?' opens with a flat 'Yes'. That is not false — properly prescribed and properly compounded medication can be safe — but a one-word 'Yes' is a strong answer to a question whose honest reply is more like 'it depends entirely on the pharmacy, and it has not been through FDA review'. Oak does not name its pharmacies, which is exactly the variable that determines the answer.

The claim we would push back on hardest is that Oak's 'compounded formulations are designed to support the same clinical outcomes' as the brand-name products. Designed to, perhaps. Demonstrated to, no. Every weight-loss figure in this field comes from trials of Wegovy, Zepbound, Ozempic and Mounjaro — not from compounded copies, which have not been tested for outcomes at all. Same active ingredient is a fair statement; same clinical outcomes is an assertion.

The supply claim is also absolute in a way that invites scrutiny. Oak states its compounded GLP-1s 'are always available' and that you will 'never miss a dose', because its pharmacy partners stock active ingredients independently of brand-name supply chains. The underlying logic is reasonable — compounders do source API separately. But 'always' and 'never' are not commitments any pharmacy supply chain can honour, and a company four months old has not been tested against a real shortage.

NAD+, sermorelin, glutathione and the peptide line carry the same regulatory status with thinner evidence behind them, and none is priced publicly.

The Consultation Process

Eligibility

• •Oak states its programme is not for anyone under 18, anyone pregnant or nursing, or anyone whose 'BMI is under 22 with no prior comorbidities'. That floor deserves attention: the FDA-approved indications for these medications are a BMI of 30 or above, or 27 or above with a weight-related condition. A threshold of 22 sits well below both.
• •If your BMI is between 22 and 27 and you have no weight-related condition, a GLP-1 is outside the population in which its benefits and risks were established. That does not make prescribing unlawful — clinicians may exercise judgement — but you should ask directly why it is being recommended and what the evidence is at your weight.
• •GLP-1 medicines are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and must not be used in pregnancy or while trying to conceive.
• •Clinician judgement is required for anyone with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease including gastroparesis, or diabetic retinopathy.
• •Common side effects are gastrointestinal — nausea, vomiting, diarrhoea, constipation and reflux — usually worst after a dose increase. Less common but serious risks include pancreatitis, gallbladder disease and dehydration-related kidney injury.
• •Rapid weight loss costs lean muscle as well as fat, and the risk is greater the less excess fat you started with — another reason the BMI floor matters. Use the included health coaching to address protein intake and resistance training.
• •Anyone with a history of disordered eating should approach weight-loss medication with clinical support, and this is especially true where the starting BMI is normal or near-normal.
• •If you stop a GLP-1, appetite generally returns and weight regain is common. Treat this as long-term treatment.

Clinicians, Labs & Pharmacy

Shipping & Support Services

Free, with tracking, and Oak says delivery takes days. It claims dedicated inventory so that supply disruptions do not affect treatment.

• •One price across all dosages — your cost does not rise as you titrate
• •No membership or subscription fee; the medication price is the whole price
• •Semaglutide from $119 and tirzepatide from $185 — competitive with the cheapest credible providers
• •Free shipping and free health coaching included
• •Price-matching offered on any medication
• •Same-day approval with no video call required
• •States plainly in its FAQ that compounded products are not FDA-approved as finished products
• •No long-term commitment, per the company
• •Publishes a phone number and email
• •Lists clear exclusions for pregnancy, nursing and under-18s

Fees, Cancellation & Refunds

Insurance & HSA/FSA

Pros & Cons

Who Oak Longevity May Be Best For

• •Price-driven buyers who want flat dose pricing and no subscription, and who meet the standard BMI criteria
• •People who have found dose-escalation surcharges elsewhere and want a provider that does not do that
• •Anyone who values included health coaching, which most competitors charge for or omit
• •Buyers comfortable with a brand-new company and willing to get every term in writing first

Limitations

• •The BMI line is the finding that concerns us most, and it is Oak's own wording. Under 'Oak is NOT for you if', the site lists: 'Your BMI is under 22 with no prior comorbidities.' Read that carefully — it means someone with a BMI of 23, 24 or 25 and no weight-related condition is, by the company's own framing, potentially eligible. The FDA-approved indications for these medications are a BMI of 30 or above, or 27 or above with a comorbidity. A BMI of 22 to 25 is normal weight. Prescribing outside an approved indication is lawful and clinicians exercise judgement all the time, but a threshold this low, published as a marketing criterion rather than a clinical one, is not the same as a doctor making an individual decision. If your BMI is in that range, ask directly what evidence supports treating you and what the risks are — including that muscle loss during rapid weight loss is proportionally more consequential the less excess fat you carry.
• •The outcome calculator makes a claim the company cannot support. Slide it to a 351 lb starting weight and it returns 'Your potential weight loss is 53 lbs', labelled 'Estimated from average patient outcomes' and 'Based on real results from Oak patients'. The percentage is not unreasonable — around 15%, in line with published semaglutide trial averages. The problem is the sourcing. Oak launched in April 2026. At the time of this review it has existed for under four months, while the trials producing those figures ran 68 to 72 weeks. A company cannot have average patient outcome data for a treatment that takes more than a year to reach its effect when it has been operating for a third of one. Whatever that number is drawn from, it is not what the label says.
• •The social proof does not reconcile either. The same homepage carries '10,000+ Satisfied Patients' and 'Trusted by 5,000+ members'. Both cannot be right, and neither is verifiable. Nor are the three different prices — $119, $185 in the headline and $167 in the comparison table — though that one is more likely carelessness than intent.
• •Set against all that, the commercial structure is genuinely one of the better ones we have reviewed and we do not want to bury it. Flat pricing across all doses solves a real problem that costs people hundreds of dollars a year at other providers. No membership fee, no subscription, no long-term commitment, free shipping and free coaching is a cleaner offer than most of this market manages, and $119 semaglutide is competitive with the cheapest credible options in this series. Oak also says the thing many competitors will not — that compounded products are not FDA-approved as finished products.
• •So the assessment turns on trust rather than value. The offer is good. The company is four months old, names no pharmacy, publishes no refund policy, quotes patient numbers that contradict each other and outcome data it cannot have, and sets an eligibility floor at a normal body weight. Those are the things a buyer has no way to check, and they are the things that matter when something goes wrong.

Alternatives to Consider

Frequently Asked Questions

Our Verdict

Oak Longevity has built one of the better commercial structures in this market. One price covering every dose means your cost does not climb as you titrate — a hidden expense that catches people out at provider after provider. There is no membership fee, no subscription and, the company says, no long-term commitment. Shipping and health coaching are included. Semaglutide at $119 and tirzepatide at $185 are competitive with the cheapest credible providers we have reviewed, and Oak states in its own FAQ the thing many competitors avoid — that compounded products are not FDA-approved as finished products.

Then there is the eligibility line. Oak's homepage lists among the people it is not for: 'Your BMI is under 22 with no prior comorbidities.' A BMI of 22 is normal weight, and the approved indications for these medications begin at 27 with a comorbidity or 30 without. Published as a marketing criterion, a floor that low signals a willingness to treat people well outside the population in which these drugs were studied. If your BMI is between 22 and 27 with no weight-related condition, that is a conversation to have with a clinician who is not selling you the medication.

The rest of the marketing has the texture of a site assembled quickly. Three different prices appear across the pages. The homepage claims both 10,000+ patients and 5,000+ members. A calculator projects a 53-pound loss on the basis of 'real results from Oak patients' at a company four months old, when the underlying trials ran well over a year. Supply is promised in absolutes. None of these is fatal on its own; together they suggest claims are not being checked.

And there is nothing external to check them against. No BBB profile, no review presence, no published refund or cancellation policy, no named pharmacy.

We rate Oak Longevity 3.0 out of 5 — a genuinely well-designed price structure attached to a very new company making claims it cannot yet support, and setting its eligibility floor at a normal body weight.

If the flat dose pricing is what appeals, established providers offer the same structure at similar or lower prices with records you can inspect. If you do try Oak, get your price, your refund terms and your pharmacy in writing first — and if your BMI is under 27 with no related condition, ask why you are being offered this at all.

This review is informational only and is not medical advice. Compounded semaglutide and tirzepatide are not FDA-approved. Speak to a licensed clinician about whether treatment is appropriate for you before starting, changing or stopping any medication.